4-bromo-N2-p-tolyl-benzene-1,2-diamine | 1416337-36-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-bromo-N2-p-tolyl-benzene-1,2-diamine
• 英文别名: 4-bromo-N2-(4-methylphenyl)-1,2-benzenediamine；4-bromo-2-N-(4-methylphenyl)benzene-1,2-diamine
• CAS: 1416337-36-4
• 化学式: C₁₃H₁₃BrN₂
• 分子量: 277.164
• InChiKey: GPMGKHFETAXYTE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  38
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-bromo-N2-p-tolyl-benzene-1,2-diamine 在 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 potassium carbonate 作用下， 以 1,4-二氧六环 、 甲醇 、 水 为溶剂， 反应 7.5h， 生成 N-[5-[2-amino-1-(4-methylphenyl)-1H-benzimidazol-6-yl]-2-(methyloxy)-3-pyridinyl]-2,4-difluorobenzenesulfonamide
  参考文献：
  名称：

  [EN] BENZIMIDAZOLE DERIVATIVES AS ANTIVIRAL AGENTS
  [FR] DÉRIVÉS DE BENZIMIDAZOLE EN TANT QU'AGENTS ANTIVIRAUX

  摘要：

  公开号：

  WO2012174312A3
• 作为产物：
  描述：

  2-氟-4-溴硝基苯 在 sodium dithionite 、 potassium carbonate 作用下， 以 乙醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 17.0h， 生成 4-bromo-N2-p-tolyl-benzene-1,2-diamine
  参考文献：
  名称：

  [EN] BENZIMIDAZOLE DERIVATIVES AS ANTIVIRAL AGENTS
  [FR] DÉRIVÉS DE BENZIMIDAZOLE EN TANT QU'AGENTS ANTIVIRAUX

  摘要：

  公开号：

  WO2012174312A3

文献信息

• BENZIMIDAZOLES AS CNS ACTIVE AGENTS
  申请人：HOFFMANN-LA ROCHE INC.

  公开号：US20150203472A1

  公开（公告）日：2015-07-23

  The present invention relates to compounds of general formula wherein R 1 hydrogen, lower alkyl, halogen or lower alkyl substituted by halogen; R 2 is hydrogen or halogen; X 1 is N or CH; X 2 is N or CH; with the proviso that only one of X 1 or X 2 is N; X 3 is C(R) or N; and R is hydrogen, lower alkyl, halogen, lower alkyl substituted by halogen, lower alkoxy or SO 2 -lower alkyl; or to a pharmaceutically acceptable acid addition salt, to a racemic mixture or to its corresponding enantiomer and/or optical isomers thereof. The compounds may be used for the treatment of schizophrenia, obsessive-compulsive personality disorder, major depression, bipolar disorders, anxiety disorders, normal aging, epilepsy, retinal degeneration, traumatic brain injury, spinal cord injury, post-traumatic stress disorder, panic disorder, Parkinson's disease, dementia, Alzheimer's disease, mild cognitive impairment, chemotherapy-induced cognitive dysfunction, Down syndrome, autism spectrum disorders, hearing loss, tinnitus, spinocerebellar ataxia, amyotrophic lateral sclerosis, multiple sclerosis, Huntington's disease, stroke, radiation therapy, chronic stress, abuse of neuro-active drugs, such as alcohol, opiates, methamphetamine, phencyclidine and cocaine.

  本发明涉及一般式化合物 其中 R 1 为氢、较低的烷基、卤素或被卤素取代的较低烷基; R 2 为氢或卤素; X 1 为N或CH; X 2 为N或CH; 但X 1 或X 2 仅有一个为N; X 3 为C(R)或N; 而R为氢、较低的烷基、卤素、被卤素取代的较低烷基、较低的烷氧基或SO 2 -较低烷基; 或者为药学上可接受的酸盐，或者为外消旋混合物或其相应的对映体和/或光学异构体。 这些化合物可用于治疗精神分裂症、强迫性人格障碍、重度抑郁症、双相情感障碍、焦虑障碍、正常衰老、癫痫、视网膜退化、创伤性脑损伤、脊髓损伤、创伤后应激障碍、恐慌障碍、帕金森病、痴呆症、阿尔茨海默病、轻度认知障碍、化疗引起的认知功能障碍、唐氏综合征、自闭症谱系障碍、听力丧失、耳鸣、脊髓小脑共济失调、肌萎缩侧索硬化、多发性硬化症、亨廷顿病、中风、放射治疗、慢性压力、滥用神经活性药物，如酒精、阿片类药物、甲基苯丙胺、芬太尼和可卡因。
• US9365550B2
  申请人：——

  公开号：US9365550B2

  公开（公告）日：2016-06-14
• [EN] BENZIMIDAZOL.ES AS CNS ACTIVE AGENTS<br/>[FR] BENZIMIDAZOLES EN TANT QU'AGENTS ACTIFS SUR LE SNC
  申请人：HOFFMANN LA ROCHE

  公开号：WO2014053409A1

  公开（公告）日：2014-04-10

  The present invention relates to compounds of general formula wherein R1 hydrogen, lower alkyl, halogen or lower alkyl substituted by halogen; R2 is hydrogen or halogen; X1 is N or CH; X2 is N or CH; with the proviso that only one of X1 or X2 is N; X3 is C(R) or N; and R is hydrogen, lower alkyl, halogen, lower alkyl substituted by halogen, lower alkoxy or SO2-lower alkyl; or to a pharmaceutically acceptable acid addition salt, to a racemic mixture or to its corresponding enantiomer and/or optical isomers thereof. The compounds may be used for the treatment of schizophrenia, obsessive-compulsive personality disorder, major depression, bipolar disorders, anxiety disorders, normal aging, epilepsy, retinal degeneration, traumatic brain injury, spinal cord injury, post-traumatic stress disorder, panic disorder, Parkinson's disease, dementia, Alzheimer's disease, mild cognitive impairment, chemotherapy-induced cognitive dysfunction, Down syndrome, autism spectrum disorders, hearing loss, tinnitus, spinocerebellar ataxia, amyotrophic lateral sclerosis, multiple sclerosis, Huntington's disease, stroke, radiation therapy, chronic stress, abuse of neuro-active drugs, such as alcohol, opiates, methamphetamine, phencyclidine and cocaine.
• [EN] BENZIMIDAZOLE DERIVATIVES AS ANTIVIRAL AGENTS<br/>[FR] DÉRIVÉS DE BENZIMIDAZOLE EN TANT QU'AGENTS ANTIVIRAUX
  申请人：GLAXOSMITHKLINE LLC

  公开号：WO2012174312A3

  公开（公告）日：2013-02-28